|
|
|
| Effects of ademetionine combined with polyene phosphatidylcholine for treating women with intrahepatic cholestasis of pregnancy on the expression of endothelin and pregnancy outcomes |
| Wenchang People's Hospital, Wenchang, Hainan Province, 571300 |
|
|
|
|
Abstract To explore the therapeutic effects of ademetionine combined with polyene phosphatidylcholine (PPC) for treating pregnant women with intrahepatic cholestasis of pregnancy (ICP), and to study its influence on the expression of endothelin (ET) in venous blood, in cord blood, and in placental tissue, and the pregnancy outcomes of these women. Methods：A total of 79 pregnant women with ICP were selected and were divided into study group (41 cases) and control group (38 cases) by random number table method from January 2019 to August 2020. The women in the study group were treated by ademetionine combined with PPC, while the women in the control group were given conventional treatment. The related maternal and neonatal parameters values were compared between the two groups. Results：The scores of skin pruritus of the women on the 3rd, the 7th, and the 14d after treatment (3.00±0.27 points, 2.26±0.19 points, and 1.04±0.22 points) in the study group were significantly lower than those (3.10±0.56 points, 2.84±0.61 points, and 2.17±0.26 points) of the women in the control group (all P＜0.05). The levels of serum endothelin-1 (ET-1), total bile acid, aspartate aminotransferase, and alanine aminotransferase of the women in the study group were significantly lower than those of the women in the control group, and the expression levels of ET-1 in neonatal umbilical cord blood and placental tissue in the study group were also significantly lower than those in the control group (all P＜0.05). The incidences of polyhydramnios (2.4%), postpartum hemorrhage (2.4%), neonatal distress (2.4%), and preterm birth (2.4%) in the study group were significantly lower than those (21.1%, 28.9%, 18.4%, and 23.7%) in the control group. The rate of vaginal delivery (51.2%) of the women in the study group was significantly higher than that (21.1%) of the women in the control group (all P＜0.05). There were no significant differences in the incidences of gestational hypertension, amniotic fluid contamination, placenta previa, neonatal asphyxia, and neonatal death between the two groups (P＞0.05). Conclusion: Ademetionine combined with PPC for treating the pregnant women with ICP can reduce the expression level of ET in maternal venous blood, in cord blood, and in placenta tissue, and which can significantly improve the clinical symptoms and the pregnancy outcomes of these women.
|
|
|
|
|
|
|
|
|
